Metabolomics in the Identification of Biomarkers of Asthma.

Thus, metabolomics is an emerging approach that may provide more insight into asthma pathophysiological mechanisms, enable the identification of early biomarkers and targeted personalized therapies, thus reducing the disease burden and societal cost. The inflammatory phenotypes identified to date include eosinophilic or T2 or T2-high asthma, and non-eosinophilic, non-T2 or T2-low asthma, which comprises, in turn, the neutrophilic and paucigranulocytic phenotypes. Asthma is a major non-communicable disease characterized by recurrent attacks of breathlessness and wheezing. Identification of biomarkers and new causative factors may possibly lead to more personalized and precise pathway-specific approaches for asthma diagnosis and treatment. [Extracted from the article]